"You have submitted results of 8 controlled trials that appear, by design, capable of demonstrating the effect of an antiepileptic drug, but results are inconsistent, leave the appropriate dose unclear, and with one exception, show either no, or numerically very small effects. While the studies do suggest that rufinamide has activity, we see no good basis for identifying the useful range of doses and even the evidence of efficacy is not reasonably assured." 1) Uncertainty/disagreement about appropriate dose (S,E) 2) Inconsistent results in different trials or at different study sites (E) Nebivolol Link: http://www.access data.fda.gov/drugsatfda_ docs/nda/2007/021742s0 00_APPROVable.pdf "A highly statistically significant and doserelated increase in benign and malignant Leydig cell tumors was observed in male mice. The findings appear with exposure only several times the clinically attained blood levels. This effect may be endocrinologically mediated. Other possibly endocrinologically mediated effects were also seen in long-term toxicology studies of rats-reductions in adrenal and ovary weights, dystocia, and interference with cyclicity. If an endocrine mechanism can be established and if this mechanism is not relevant to human use, e.g., because it is not active at clinical doses, the mouse findings may not be of concern. It will therefore be necessary for you to establish the mechanism by which nebivolol is responsible for these findings and demonstrate that these findings are not relevant in humans." 1) Potential risks based on animal toxicology e.g. carcinogenicity (S) Febuxostat Link: http://www.accessdata.f da.gov/drugsatfda_docs/ nda/2009/021856s000_S umR.pdf "Due to the finding that exposure to Uloric appeared to increase the risk of cardiac thromboembolic events compared to placebo, or allopurinol, the sponsor was asked to either provide further comparative controlled clinical safety data or to reanalyze the original database and demonstrate that the apparent signal of increased risk is not predictive of clinically 1) Adverse events: Cardiovascular (S) 2) Adverse events: Hemostasis (S)
3) CYP enzyme studies not done (S) Formatted Table   Formatted ...
important differences.
Due to the finding of hemorrhagic adverse events and elevated INRs in patients on Uloric and warfarin in the original database for the application, and questions concerning the reliability of the results of a pharmacokinetic study that specifically looked at warfarin interaction with Uloric, the sponsor was asked to further evaluate the potential for concomitant administration of warfarin and Uloric to result in haemorrhagic adverse events…
Due to an absence of data to evaluate the induction potential of Uloric on human CYP P450 enzymes, the sponsor was asked to perform a study to provide this data either in vitro or in vivo."
Atomoxetine hydrochloride Link: http://www.accessdata.f da.gov/drugsatfda_docs/ nda/2002/21-411_Strattera_Approv.p df "Although we believe that no important effect on the QT interval was demonstrated at mean plasma levels at or below about 2000 ng/ml, there are relatively few data at or above these levels, and, as a result, we cannot reach a definitive decision at this time about whether there is or is not an effect of atomoxetine on the QT interval at these higher levels, and, if there is, what the plasma level threshold for such and effect might be. For this reason you will need to prepare a comprehensive report in which you address the question of the relationship between higher level of atomoxetine and the duration of the QT interval.
We also note that there is a paucity of longterm safety data in poor metabolizers (PM) in your database (13 PMs treated at a therapeutic dose for at least 6 months and 1 such patient treated for at least 1 year). Please submit additional long-term safety data in these patients…" or intermittent nitrate therapy. However, it is expected that men with cardiovascular disease will use Cialis. Some of those men will experience cardiovascular events and be given nitrates in emergency situations. You must provide information to label the effects of blood pressure with nitroglycerin and Cialis 20 mg for a period of time after Cialis dosing until no blood pressure interaction is seen." Rosuvastin calcium Link: http://www.accessdata.f da.gov/drugsatfda_docs/ nda/2003/21-366_Crestor_Approv.pd f "The application presented consistent evidence of little added benefit of the 80-mg dose over the 40-mg dose, even in patients with homozygous familial hypercholesterolemia. This small benefit does not outweigh the risks of myopathy and renal toxicity apparent at this dose.
The numbers of patients exposed long term to rosuvastin are inadequate to provide assurance of the safety of either the 20-mg or the 40-mg proposed dose. Additional safety information is needed to permit conclusions regarding the drug's therapeutic index, given the high incidence of rhabdoyolysis seen at the 80-mg dose." 1) Uncertainty/disagreement about appropriate dose (S,E) 2) Population inadequate for proposed dose/duration of therapy (S) Ranolazine Link: http://www.accessdata.f da.gov/drugsatfda_docs/ nda/2006/021526_s000_ Ranexa_ApprovBle.pdf "The trials in angina, however, do not adequately characterize the relationship between dose and therapeutic effect sufficiently to provide labeling instructions for its use. It will be necessary to obtain additional dose-response information.
Potential testicular toxicity, manifest as impaired fertility in rats in study AT-413616-R-86-43285-PO-RFM. The available data are inadequate to determine whether this was a chance finding or evidence of testicular toxicity to ranolazine. While no clinical signs of male reproductive toxicity were reported, this is not surprising or reassuring, as adequate assessment of this toxicity typically requires targeted clinical evaluation." 1) Uncertainty/disagreement about appropriate dose (S,E) 2) Potential risks based on animal toxicology (e.g. carcinogenicity) (S) 3) Safety population inadequate for proposed dose/duration of therapy (S) chronically used drug. Thus, we ask that you obtain additional exposures within this iloperidone dose range of20-24 mg/day. You would need at least 1000 additional patients exposed, and the chronic use would need to meet the minimum standard of at least 300 for 6 months and at least 100 for 1 year First there is some evidence that iloperidone is substantially inferior to existing alternative treatments, although we do not consider this entirely established, The agency has, in the recent past, taken the relative effectiveness of new psychiatric drugs compared to currently available drugs into consideration when making overall risk benefit decisions about new psychiatric drugs. The overall principle is that markedly inferior performance on the treatment of an acute schizophrenia episode presents a risk to patients " 1 Additional data on these and other approved products are accessible on the web at drugs@fda. This may include FDA reviews and action letters.
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S=safety deficiency, E= efficacy deficiency, C=CMC deficiency, S,E=both safety and efficacy deficiencies
